Mild and Rapidly Improving Stroke Study

Conditions

Ischemic Stroke

Brief summary

The objective of this study is to determine the 90-day outcomes of mild and rapidly improving ischemic stroke.

Abbey Staugaitis, Shayan Khan, Megan Tessmer, Denise Gaffney, Joseph P. Broderick et al. (8 authors)

Neurology2023-04-25

10.1212/wnl.0000000000204304

Abstract TMP38: Remote Research Practices Enhance Acute Stroke Clinical Trial Enrollment

Christopher Streib, Abbey Staugaitis, Megan Tessmer, Shayan Khan, Denise Gaffney et al. (8 authors)

Stroke2023-02-01

10.1161/str.54.suppl_1.tmp38

Functional status at 30 and 90 days after mild ischaemic stroke

Hannah Gardener, Leo A Romano, Eric E. Smith, Iszet Campo‐Bustillo, Yosef Khan et al. (20 authors)

Stroke and Vascular Neurology2022-04-2635 citations

10.1136/svn-2021-001333

Frequency and Prognostic Significance of Clinical Fluctuations Before Hospital Arrival in Stroke.

Romano JG, Gardener H, Smith EE, Campo-Bustillo I, Khan Y, Tai S, Riley N, Sacco RL, Khatri P, Alger HM, Mac Grory B, Gulati D, Sangha NS, Olds KE, Benesch CG, Kelly AG, Brehaut SS, Kansara AC, Schwamm LH, MaRISS Investigators*.

2021-10-145 citations

10.1161/strokeaha.121.034124

Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS

José G. Romano, Hannah Gardener, Iszet Campo‐Bustillo, Yosef Khan, Sofie Tai et al. (100 authors)

Stroke2021-05-0550 citations

10.1161/strokeaha.120.032809

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Mild or spontaneously rapidly improving ischemic stroke confirmed by neuroimaging * Arrival to hospital within 4.5 hours of symptom onset * Willing to provide consent * Available for a telephone interview at 30 and 90 days

Exclusion criteria

* Onset \>4.5 hours * Unable to provide informed consent (patient or legally appointed representative * Premorbid modified Rankin Scale \>1 * Unavailable by telephone for follow-up

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients not independent at 90 days	90 days	The primary outcome measure is proportion of patients with a modified Rankin Scale of 2-6 at 90 days

Secondary

Measure	Time frame	Description
Symptomatic intracranial hemorrhage due to Alteplase	36 hours	Amongst those that receive intravenous Alteplase, a secondary safety measure is the proportion of patients that develop neurologic worsening development of symptomatic intracerebral hemorrhage, defined as neurological deterioration that, in the judgment of the investigator, is related to intracranial hemorrhage confirmed by CT or MRI, within 36 hours of administration of Alteplase.
Proportion of patients not independent at 30 days	30 days	Proportion of patients with modified Rankin Scale 2-6 at 30 days.
Proportion of patients with dependence or disability in activities of daily living at 90 days	90 days	Proportion of patients not independent in activities of daily living defined as a Barthel Index score \<95
Stroke disability by the Stroke-Impact Scale-16	90 days	SIS-16 will be treated as a continuous measure
Independence with Activities of Daily Living by the Barthel Index	90 days	BI will be treated as a continuous measure; pre specified analysis include proportion of patients with Barthel Index \<95
Quality of life by the EuroQOL EQ-5D	90 days	EuroQOL will be treated as a continuous measure

Countries

United States

Outcome results